Visit https://www.peervoice.com/HES860 to view the entire programme with slides. After completing “Targeting Pro-Tumorigenic Inflammation in NSCLC: Evolving Strategies to Improve Patient Outcomes”, participants will be able to: Discuss the role of pro-tumour inflammation (PTI) in promoting cancer growth and metastasis; Evaluate the potential for reductions in cancer incidence, cancer morbidity, and mortality with IL-1β–targeted agents aimed at reducing PTI

Visit https://www.peervoice.com/UWX860 to view the entire programme with slides. After completing “Stroke Prevention, Type 2 Diabetes, and GLP-1 Receptor Agonists: What Neurologists Need to Know”, participants will be able to: Explain the role of GLP-1 RAs in stroke prevention in type 2 diabetes (T2DM); Evaluate the cardiovascular outcomes data for GLP-1 RAs in terms of stroke prevention in patients with T2DM; and Apply optimal treatment plans for reducing the risk of stroke in patients with T2DM.

Visit https://www.peervoice.com/KRF860 to view the entire programme with slides. After completing “Beyond HPIs for Advanced Basal Cell Carcinoma: Exploring the Clinical Implications of New Evidence”, participants will be able to: Identify the immunotherapies in late clinical development for the management of advanced basal cell carcinoma (aBCC); Describe emerging efficacy and safety data for systemic therapeutic strategies; and Appraise and translate the latest evidence on emerging immunotherapies as second-line systemic treatments for aBCC in patients with progressive disease.

Visit https://www.peervoice.com/JTJ860 to view the entire programme with slides. After completing “Modern Management of Chronic Kidney Disease: A Look to the Future”, participants will be able to: Explain the rationale for novel therapies for the management of chronic kidney disease (CKD); Evaluate the safety and efficacy of recent clinical data for managing CKD, focusing on novel therapies; and Analyse the clinical implications of emerging evidence for managing CKD.

Visit https://www.peervoice.com/JHW860 to view the entire programme with slides. After completing “Evolving Approaches to Manage Osteoporosis: Clinical Pearls for Canadian Practice”, participants will be able to: Evaluate the efficacy of bone-formation therapies and how they may impact clinical management of osteoporosis in postmenopausal women; and Discuss the safety data with bone-formation therapies for osteoporosis and clinical implications for treatment decisions and ongoing patient management.

Visit https://www.peervoice.com/TDK860 to view the entire programme with slides. After completing “Cardiovascular Risk and Prostate Cancer: Clinical Perspectives on ADT”, participants will be able to: Evaluate the burden and prevalence of CV disease in men with advanced prostate cancer; Differentiate between the impact of GnRH agonists and antagonists on CV risk; and Identify how future therapeutic strategies could evolve that reduce CV risk and which men would benefit most.

Visit https://www.peervoice.com/QGY860 to view the entire programme with slides. After completing “Proactive IBD Care: Identifying Patients at Risk of Disease Progression”, participants will be able to: Explain the rationale for assessing risk of progression and individualising therapy for patients with inflammatory bowel disease (IBD); Apply emerging risk assessment strategies to identify patients with IBD at risk of progression; and Design effective treatment plans for patients with IBD according to risk stratification.

Visit https://www.peervoice.com/QFN860 to view the entire programme with slides. After completing “Simplifying Fluid Therapy: Critical Care for the Critically Ill ”, participants will be able to: Describe the current recommendations for fluid management and how they apply in the real world; Recognise the variations in crystalloid and colloid fluids and their appropriate use; and Translate the latest evidence for fluid replacement and its potential impact on clinical strategies.

Visit https://www.peervoice.com/KKY860 to view the entire programme with slides. After completing “The Impact of Earlier Diagnosis and Timelier Treatment of Primary Hyperoxaluria Type 1”, participants will be able to: Describe the pathological processes of primary hyperoxaluria type 1 (PH1) that lead to end-stage renal disease; Recognise key signs and signals in patients with PH1 and the need for early diagnosis; and Discuss current management strategies for PH1 and the emerging pharmacological therapy.

Visit https://www.peervoice.com/GWP860 to view the entire programme with slides. After completing “Interpreting the Most Recent Clinical Data With A Real-World Lens: Implications on Hepatocellular Carcinoma Management ”, participants will be able to: Discuss the most recent and relevant clinical data that most impacts the systemic treatment of patients with unresectable hepatocellular carcinoma (HCC); Formulate personalised, evidence-based sequencing strategies, developed through a multidisciplinary approach, that optimise the survival of patients with unresectable HCC; and Apply a balanced approach to maximise patient quality of life over the duration of the treatment plan.